<html><head></head><body><h1>Amphotericin B Cholesteryl Sulfate Complex</h1><ul class="ddc-anchor-links"><li>Pharmacology</li>
<li>Uses</li>
<li>Contraindications</li>
<li>Dosage</li>
<li>Storage</li>
<li>Interactions</li>
<li>Warnings</li>
<li>Pregnancy</li>
<li>Patient education</li></ul><h2>Pronunciation</h2><p>(am foe TER i sin bee kole LES te ril SUL fate KOM plecks)</p><h2>Index Terms</h2><ul><li>ABCD</li><li>Amphotericin B Colloidal Dispersion</li></ul><h2>Pharmacologic Category</h2><ul><li>Antifungal Agent, Parenteral</li></ul><h2 class="ddc-anchor-offset" id="pharmacology">Pharmacology</h2><p>Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages (Lyman, 1992).</p><h3>Distribution</h3><p>V<sub>d</sub>: Total volume increases with higher doses, reflects increasing uptake by tissues (with 4 mg/kg/day = 4 L/kg); predominantly distributed in the liver; concentrations in kidneys and other tissues are lower than observed with conventional amphotericin B (Walsh 2008)</p><h3>Half-Life Elimination</h3><p>~28 hours; prolonged with higher doses</p><h2 class="ddc-anchor-offset" id="uses">Use: Labeled Indications</h2><p>Treatment of invasive aspergillosis in patients who have failed amphotericin B deoxycholate treatment, or who have renal impairment or experience unacceptable toxicity which precludes treatment with amphotericin B deoxycholate in effective doses.</p><h2>Off Label Uses</h2><h3>Candida species infections (serious)</h3><p>Based on the Infectious Diseases Society of America (IDSA) clinical practice guidelines for the management of candidiasis, a lipid formulation of amphotericin B (eg, amphotericin B cholesteryl sulfate complex) is effective and recommended for the treatment of serious <i>Candida</i> species infections.</p><h2 class="ddc-anchor-offset" id="contraindications">Contraindications</h2><p>Hypersensitivity to amphotericin B or any component of the formulation (unless the benefits outweigh the possible risk to the patient)</p><h2 class="ddc-anchor-offset" id="dosage">Dosing: Adult</h2><p><b>Note:</b> Amphotec has been discontinued in the US for more than 1 year.</p><p><b>Note:</b> Lipid-based amphotericin formulations (Amphotec) may be confused with conventional formulations (desoxycholate [Amphocin, Fungizone]). Lipid-based and conventional formulations are <b>not </b>interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p><p><b>Aspergillosis (invasive), treatment:</b> <i>Usual dosage range:</i> 3 to 4 mg/kg/day. <b>Note:</b> 6 mg/kg/day has been used for treatment of life-threatening invasive aspergillosis in immunocompromised patients (Bowden, 2002).</p><p><b><i>Premedication:</i></b> For patients who experience chills, fever, hypotension, nausea, or other nonanaphylactic infusion-related immediate reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: A nonsteroidal with or without diphenhydramine <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone 50 to 100 mg with or without a nonsteroidal and diphenhydramine (Paterson, 2008).</p><p><b><i>Test dose:</i></b> For patients receiving their first dose in a new treatment course, a small amount (10 mL of the final preparation, containing between 1.6 to 8.3 mg) infused over 15 to 30 minutes is recommended. The patient should then be observed for an additional 30 minutes.</p><h2>Dosing: Geriatric</h2><p>Refer to adult dosing.</p><h2>Dosing: Pediatric</h2><p><b>Note: </b>Amphotec has been discontinued in the US for more than 1 year.</p><p><b>Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (Abelcet, Amphotec, AmBisome) and conventional amphotericin B for injection.</b> Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p><p><b>Note:</b> Premedication for patients who experience fever, chills, hypotension, nausea, or other nonanaphylactic infusion-related immediate reactions may be given 30 to 60 minutes prior to drug administration: NSAIDs (with or without diphenhydramine) <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone may be given (Paterson 2008); if patient experiences rigors during infusion, meperidine may be administered. The manufacturer’s labeling advises a test dose be administered immediately preceding the first dose when a new course of treatment occurs. A small amount of drug (eg, 10 mL of final preparation containing between 1.6 and 8.3 mg of drug) should be infused over 15 to 30 minutes and patient should be carefully observed for the next 30 minutes.</p><p><b><i>Aspergillosis</i>, treatment:</b></p><p>Invasive: Infants, Children, and Adolescents: IV: Usual dose range: 3 to 4 mg/kg/dose once daily; doses as high as 7.5 mg/kg/dose have been described in open label studies (Sandler 2000)</p><p>Endocarditis: Children and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015])</p><p><b>Candidiasis, treatment: </b>Infants, Children, and Adolescents:</p><p>Invasive: IV: 3 to 5 mg/kg/dose once daily (IDSA [Pappas 2016])</p><p>Endocarditis: Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015]; IDSA [Pappas 2016])</p><p>Esophageal (HIV-exposed/-positive): Adolescents: IV: 3 to 4 mg/kg/dose once daily for 14 to 21 days (HHS [OI adult 2016])</p><p><b>Coccidiodomycosis, disseminated (non-CNS) or diffuse pulmonary disease: </b>HIV-exposed/-infected:</p><p>Infants and Children: IV: 5 mg/kg/dose once daily until clinical improvement; dose may be increased as high as 10 mg/kg/dose once daily for life-threatening infection (HHS [OI pediatric 2013])</p><p>Adolescents: IV: 3 to 5 mg/kg/dose once daily until clinical improvement, then change to fluconazole or itraconazole (HHS [OI adult 2016])</p><p><b>Histoplasmosis, disseminated disease (moderately severe to severe): </b>HIV-exposed/-positive: Adolescents: IV: 3 mg/kg/dose once daily for at least 2 week induction, followed by oral itraconazole (HHS [OI adult 2016])</p><h2>Reconstitution</h2><p>Reconstitute 50 mg and 100 mg vials with 10 mL and 20 mL of SWI, respectively. The reconstituted vials contain 5 mg/mL of amphotericin B. Shake the vial gently by hand until all solid particles have dissolved. Further dilute amphotericin B colloidal dispersion with D<sub>5</sub>W. </p><h2>Administration</h2><p>IV: Initially infuse at 1 mg/kg/hour. Rate of infusion may be increased with subsequent doses as patient tolerance allows (minimum infusion time: 2 hours). For a patient who experiences chills, fever, hypotension, nausea, or other nonanaphylactic infusion-related reactions, premedicate with the following drugs 30-60 minutes prior to drug administration: A nonsteroidal with or without diphenhydramine <b>or</b> acetaminophen with diphenhydramine <b>or</b> hydrocortisone 50-100 mg with or without a nonsteroidal and diphenhydramine (Paterson, 2008). If the patient experiences rigors during the infusion, meperidine may be administered. If severe respiratory distress occurs, the infusion should be immediately discontinued.</p><h2 class="ddc-anchor-offset" id="storage">Storage</h2><p>Store intact vials at 15°C to 30°C (59°F to 86°F). After reconstitution, the solution should be refrigerated at 2°C to 8°C (36°F to 46°F) and used within 24 hours. Concentrations of 0.1-2 mg/mL in D<sub>5</sub>W are stable for 24 hours at 2°C to 8°C (36°F to 46°F).</p><h2 class="ddc-anchor-offset" id="interactions">Drug Interactions</h2><p>Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Consider therapy modification</i></p><p>Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides. <i> Monitor therapy</i></p><p>Amisulpride (Oral): May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Monitor therapy</i></p><p>Antifungal Agents (Azole Derivatives, Systemic): May diminish the therapeutic effect of Amphotericin B.<i> Monitor therapy</i></p><p>Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Monitor therapy</i></p><p>Arsenic Trioxide: Amphotericin B may enhance the hypotensive effect of Arsenic Trioxide. Amphotericin B may enhance the QTc-prolonging effect of Arsenic Trioxide.  Management: When possible, avoid concurrent use of arsenic trioxide with drugs that can cause electrolyte abnormalities, such as amphotericin B.<i> Consider therapy modification</i></p><p>Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Monitor therapy</i></p><p>Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Avoid combination</i></p><p>Cardiac Glycosides: Amphotericin B may enhance the adverse/toxic effect of Cardiac Glycosides. <i> Monitor therapy</i></p><p>Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate.  Management: Avoid coadministration of colistimethate and amphotericin B whenever possible due to the potential for additive or synergistic nephrotoxicity. If coadministration cannot be avoided, closely monitor renal function.<i> Consider therapy modification</i></p><p>Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.<i> Monitor therapy</i></p><p>CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Monitor therapy</i></p><p>Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Dichlorphenamide: Amphotericin B may enhance the hypokalemic effect of Dichlorphenamide. <i> Monitor therapy</i></p><p>Dronabinol: May increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Monitor therapy</i></p><p>DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Monitor therapy</i></p><p>Fexinidazole [INT]: Amphotericin B may enhance the arrhythmogenic effect of Fexinidazole [INT]. <i> Avoid combination</i></p><p>Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function. <i> Monitor therapy</i></p><p>Foscarnet: May enhance the nephrotoxic effect of Amphotericin B.<i> Avoid combination</i></p><p>Ganciclovir-Valganciclovir: May enhance the nephrotoxic effect of Amphotericin B.<i> Monitor therapy</i></p><p>Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Monitor therapy</i></p><p>Levodopa-Containing Products: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Containing Products. <i> Monitor therapy</i></p><p>Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Methoxyflurane: May enhance the nephrotoxic effect of Amphotericin B.<i> Avoid combination</i></p><p>Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Monitor therapy</i></p><p>Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Consider therapy modification</i></p><p>Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Monitor therapy</i></p><p>Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Monitor therapy</i></p><p>Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Avoid combination</i></p><p>Sodium Stibogluconate: Amphotericin B may enhance the cardiotoxic effect of Sodium Stibogluconate.  Management: Consider separating courses of sodium stibogluconate and amphotericin B by at least 14 days. Correct electrolyte imbalances prior to initiating amphotericin B and closely monitor cardiac status.<i> Consider therapy modification</i></p><h2>Adverse Reactions</h2><p>The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p><p>Amphotericin B colloidal dispersion has an improved therapeutic index compared to conventional amphotericin B, and has been used safely in patients with amphotericin B-related nephrotoxicity; however, continued decline of renal function has occurred in some patients.</p><p>&gt;10%: </p><p>Cardiovascular: Hypotension, tachycardia </p><p>Central nervous system: Chills </p><p>Endocrine &amp; metabolic: Hypokalemia</p><p>Gastrointestinal: Vomiting</p><p>Hepatic: Hyperbilirubinemia</p><p>Renal: Increased serum creatinine</p><p>Miscellaneous: Fever</p><p>5% to 10%: </p><p>Cardiovascular: Chest pain, facial edema, hypertension</p><p>Central nervous system: Abnormality in thinking, drowsiness, headache, insomnia </p><p>Dermatologic: Diaphoresis, pruritus, skin rash </p><p>Endocrine &amp; metabolic: Hyperglycemia, hypocalcemia, hypomagnesemia, hypophosphatemia</p><p>Gastrointestinal: Abdominal pain, diarrhea, enlargement of abdomen, hematemesis, nausea, stomatitis, xerostomia </p><p>Hematologic &amp; oncologic: Anemia, hemorrhage, thrombocytopenia</p><p>Hepatic: Abnormal hepatic function tests, increased serum alkaline phosphatase, jaundice</p><p>Neuromuscular &amp; skeletal: Back pain, muscle rigidity, tremor </p><p>Respiratory: Dyspnea, epistaxis, hypoxia, increased cough, rhinitis</p><p>&lt;5%, postmarketing, and/or case reports: Acidosis, atrial arrhythmia, cardiac arrest, cardiac failure, gastrointestinal hemorrhage, hepatic failure, injection site reaction, oliguria, pain at injection site, pleural effusion, renal failure, seizure, syncope, ventricular arrhythmia</p><h2 class="ddc-anchor-offset" id="warnings">Warnings/Precautions</h2><p><b><i>Concerns related to adverse effects:</i></b></p><p>• Anaphylaxis: Has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If severe respiratory distress occurs, the infusion should be immediately discontinued; the patient should not receive further infusions. During the initial dosing, the drug should be administered under close clinical observation.</p><p>• Infusion reactions: Acute infusion reactions, sometimes severe, may occur 1-3 hours after starting infusion. These reactions are usually more common with the first few doses and generally diminish with subsequent doses. Pretreatment with antihistamines/corticosteroids and/or decreasing the rate of infusion can be used to manage reactions. Avoid rapid infusion.</p><p><b><i>Disease-related concerns:</i></b></p><p>• Heart failure: In a scientific statement from the American Heart Association, amphotericin has been determined to be an agent that may cause direct myocardial toxicity (magnitude: moderate/major) (AHA [Page 2016]).</p><h2>Monitoring Parameters</h2><p>Liver function tests, serum electrolytes (especially potassium and magnesium), BUN, serum creatinine, CBC, prothrombin time; temperature, I/O; signs of hypokalemia (muscle weakness, cramping, drowsiness, ECG changes)</p><h2 class="ddc-anchor-offset" id="pregnancy">Pregnancy Risk Factor
B

Pregnancy Considerations</h2><p>Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious systemic fungal diseases in pregnant women; refer to current guidelines (IDSA [Pappas 2016]; King 1998; Pilmis 2015).</p><h2 class="ddc-anchor-offset" id="patient-education">Patient Education</h2><p><b>What is this drug used for?</b></p><p>• It is used to treat fungal infections.</p><p><b>All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:</b></p><p>• Nausea</p><p>• Vomiting</p><p>• Diarrhea</p><p>• Lack of appetite</p><p>• Weight loss</p><p>• Muscle pain</p><p>• Joint pain</p><p>• Abdominal pain</p><p><b>WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:</b></p><p>• Liver problems like dark urine, fatigue, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin</p><p>• Kidney problems like unable to pass urine, blood in the urine, change in amount of urine passed, or weight gain</p><p>• Fluid and electrolyte problems like mood changes, confusion, muscle pain or weakness, abnormal heartbeat, severe dizziness or passing out, fast heartbeat, increased thirst, seizures, loss of strength and energy, lack of appetite, unable to pass urine or change in amount of urine passed, dry mouth, dry eyes, or nausea or vomiting</p><p>• Shortness of breath</p><p>• Chills</p><p>• Severe dizziness</p><p>• Passing out</p><p>• Fast breathing</p><p>• Fast heartbeat</p><p>• Severe headache</p><p>• Bruising</p><p>• Bleeding</p><p>• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.</p><p><b>Note:</b> This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.</p><p><b>Consumer Information Use and Disclaimer:</b> This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.</p><h2>More about amphotericin b cholesteryl sulfate</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: polyenes</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Aspergillosis, Invasive</li>
<li>Candidemia</li>
<li>Febrile Neutropenia</li>
<li>Histoplasmosis</li>
<li>Leishmaniasis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>